Tropism, coreceptor use, and phylogenetic analysis of both the V3 loop and the protease gene of three novel HIV-1 group O isolates

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 417-425

  Vallejo, Alejandro ^a   Heredia, Alonso ^a   Mas, Antonio ^b   Lee, Sherwin F ^a   Epstein, Jay S ^a   Soriano, Vicente ^b   Hewlett, Indira K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Coreceptor; Group O; HIV 1; Isolation; Monocyte derived macrophages; Sequencing; Tropism

Indexed keywords

PROTEINASE; VIRUS ENZYME;

ARTICLE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SPAIN; UNITED STATES; VIRUS GENE; VIRUS ISOLATION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0032529390     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00002     Document Type: Article

References (49)

1. Charneau P, Borman AM, Quillent C, et al. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994;205:247-53.
2. De Leys R, Van der dorght B, Haesevelde V, et al. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J Virol 1990;64:1207-16.
3. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994;68:1581-5.
4. Peeters M, Gueye A, Mboup S, et al. Geographical distribution of HIV-1 group O viruses in Africa. AIDS 1997;11:493-8.
5. Kabeya CM, Esu-Williams E, Eni E, Peeters M, Saman E, Delaporte E. Evidence for HIV-1 group O infection in Nigeria. Lancet 1995;346:308.
6. Peeters M, Lobe V, Nkengasong J, et al. HIV-1 group O infection in Belgium. Acta Clin Belg 1995;50:171-3.
7. Soriano V. Gutiérrez M, García-Lerma G, et al. First case of HIV-1 group O infection in Spain. Vox Sang 1996;71:66.
8. Loussert-Ajaka I, Chaix ML, Korber B, et al. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol 1995;69:5640-9.
9. Rayfield M, Sullivan P, Bandea C, et al. HIV-1 group O virus identified for the first time in the United States. Emerg Infect Dis 1996;2:209-12.
10. Gould K, Britvan L, Dryjanski J. HIV-1 group O infection in the USA. Lancet 1996;348:680-1.
11. Centers for Disease Control and Prevention. Identification of HIV-1 group O infection - 1996. JAMA 1996;276:521-2.
12. Pau CP, Hu DJ, Spruill C, et al. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion 1996;36:398-400.
13. Identification of HIV-1 group O infection - Los Angeles county, California, 1996. MMWR Morb Mortal Wkly Rep 1996;45:561-5.
14. Nkengasong JN, Fransen K, Willems B, et al. Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O. J Med Virol 1997;51: 202-9.
15. D'Silva M, Leibowitz D, Flaherty JP. Diagnosis of HIV-1 group O infection by polymerase chain reaction. Lancet 1995;346:451-2.
16. Yoshimura K, Matsushita S, Hayashi A, Takatsuki K. Relationship of HIV-1 envelope V2 and V3 sequences of the primary isolates to the viral phenotype. Microbiol Immunol 1996;40:277-87.
17. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
18. de Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66:6777-80.
19. Feng Y, Droder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
20. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-6.
21. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
22. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 1997;71:1657-61.
23. McKnight A, Wilkinson D, Simmons G, et al. Inhibition of human immunodeficiency virus type fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71:1692-6.
24. Björndal A, Deng M, Jansson JR, et al. Co-receptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-87.
25. Rana S, Besson G, Cook DG, et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J Virol 1997;71:3219-27.
26. Simmons G, Wilkinson D, Reeves JD, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-60.
27. Choe H, Farzan M, Sun Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
28. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 1994;7:232-7.
29. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994;12:593-633.
30. Michael NL, Davis KE, Loomis-Price LD, et al. V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients. AIDS 1996;10:121-9.
31. Buonaguro L, Del Gaudio E, Monaco M, et al. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. J Virol 1995;69:7971-81.
32. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-2. Science 1991;253:71-4.
33. Millich L, Margolin B, Swansrom R. V3 loop of the human immunodeficiency virus type 1 env protein: interpreting sequence variability. J Virol 1993;67:5623-34.
34. Willey RL, Theodore TS, Martin MA. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J Virol 1994;68:4409-19.
35. Myers GM, Korber B, Hahn BH, et al. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory, 1995.
36. Felsenstein J. http://evolution.genetics.washington.edu/phylip. html, 1998.
37. Mas A, Quiñones-Mateu ME, Soriano V, Domingo E. env gene characterization of the first HIV type 1 group O Spanish isolate. AIDS Res Hum Retroviruses 1996;12:1647-9.
38. Kozak SL, Platt EJ, Madani N, Ferro FE Jr, Peden K, Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997;71:873-82.
39. Platt EJ, Madani N, Kozak SL, Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 1997;71:883-90.
40. Balter M. A second coreceptor for HIV in early stages of infection. Science 1996;272:1740.
41. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA. HIV-1 tropism and co-receptor use. Nature 1997;385:495-6.
42. Zhang L, Huang Y, He T, Cao Y, Ho DD. HIV-1 subtype and second receptor. Nature 1996;383:768.
43. Audoly G, Fillon S, Pinay P, Desgrandes C. In vivo an in vitro sequence diversity of the V3 env region of HIV type 1 from the Ivory Coast. AIDS Res Hum Retroviruses 1996;12:1073-5.
44. Willey RL, Theodore TS, Martin MA. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J Virol 1994;68:4409-19.
45. De Jong J, Simon F, van der Groen G, et al. V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res Hum Retroviruses 1996;12:1503-7.
46. Michael NL, Davis KE, Loomis-Price LD, et al. V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients. AIDS 1996;10:121-9.
47. Yoshimura K, Matsushita S, Hayashi A, Takatsuki K. Relationship of HIV-1 envelope V2 and V3 sequences of the primary isolates to the viral phenotype. Microbiol Immunol 1996;40:277-87.
48. Smidt ML, Potts KE, Tucker SP, Blystone L, et al. A mutation in Human Immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother 1997;41:515-22.
49. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996;10: S151-7.